Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804370 · ClinicalTrials.gov registry record · Phase 3
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
A Phase 3 study of Ovarian Cancer, sponsored by NX Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 6
- Study locations
NCT05804370 is a Phase 3 study of Ovarian Cancer that is actively recruiting participants, run by NX Development. The registered enrollment target is 170 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05804370, a Phase 3 study of Ovarian Cancer, is actively recruiting participants, sponsored by NX Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 6
- Study locations
Study Summary
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.
Conditions Studied
Interventions
- DRUG Gleolan
Study Locations (6)
Maryland
- Luminis Health Anne Arundel Medical Center - Annapolis
- University of Maryland - Baltimore
Arizona
- Mayo Clinic Arizona - Phoenix
Minnesota
- Mayo Clinic Methodist Campus - Rochester
New York
- Mount Sinai - New York
Pennsylvania
- WellSpan Health - York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05804370
The ClinicalTrials.gov registry entry for NCT05804370 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The listed sponsor is NX Development, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Gleolan is the first listed.
NCT05804370 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Maryland, Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05804370 about?
NCT05804370 is a clinical study titled "Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)". This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study parti...
What is the current status of trial NCT05804370?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2024-05-30. Estimated completion is 2027-05.
What conditions does trial NCT05804370 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT05804370?
The interventions under investigation include: Gleolan (DRUG).
Who is sponsoring clinical trial NCT05804370?
This trial is sponsored by NX Development, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05804370 being conducted?
This trial has 6 study locations across Arizona, Maryland, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.